Knome Introduces First Plug and Play Human Genome Supercomputer Interpretation System–knoSYS100, It Runs Behind Client Fir
Posted Oct 01 2012 2:46am
George Church has come a long way since the Polonator, which was introduced in 2008 and sold for $150,000. This one is $25,000 less and probably does a whole lot more. The knoSys100 is both a hardware and software system that transforms sequence data produced by various platforms into a standard richly annotated and easy comparable data set. Now here’s a little technical information as it runs over 1.2 teraFLOPS, it includes four 2.4GHz 8-core/16 thread Intel® Xeon® E5-2665 processors (32 cores), and 18TB to 54TB of useable disk storage and Gigabit Ethernet. It comes in one enclosure and can be used in a laboratory environment.
Another feature, privacy here as it is installed on premise and maintained behind the client firewall for those places who do not wish to send data to third parties or to the cloud. Privacy and consent concerns are handled. Today at Oracle, they just announced both their private and public cloud offerings to take on Amazon. Knome also states that the unit can accept data from Complete Genomics, Illumina and Life Technologies which is a big selling point of their technology.
In summary, this is a big and powerful plug and play unit and it’s function is to get useful medical information from a patient’s DNA. BD
Knome Inc. announced today that it is taking orders for the knoSYS™100, the first plug-and-play, fully integrated hardware and software system designed to help researchers in medical and academic institutions interpret human whole genomes. The knoSYS™100 was developed to help geneticists discover relevant genetic variation, investigate diseases of unknown cause, and create next generation in silico gene tests. Units will begin shipping in Q4, 2012.
Starting at $125,000, the knoSYS™100 is based on Knome’s big data informatics technology. The system will accept next generation sequence data from leading sequencers, including those sold by Illumina (NASDAQ: ILMN), Life Technologies (NASDAQ: LIFE), and Complete Genomics (NASDAQ: GNOM).
More than a dozen of the world’s top medical institutions have joined an early access program to pilot Knome’s genome interpretation technology, including: ARUP Laboratories, Cedars-Sinai Medical Center, Cincinnati Children’s Hospital, The Hospital for Sick Children (SickKids) in Toronto, Hyundai Cancer Institute at CHOC Children’s, University of Liverpool, and University of Verona.